NASDAQ:CHRS - Coherus Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.90 +0.05 (+0.34 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$14.85
Today's Range$14.40 - $15.10
52-Week Range$8.05 - $17.80
Volume320,200 shs
Average Volume746,612 shs
Market Capitalization$929.68 million
P/E Ratio-3.33
Dividend YieldN/A
Beta3.49
Coherus Biosciences logoCoherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Debt-to-Equity Ratio-33.10
Current Ratio4.06
Quick Ratio4.06

Price-To-Earnings

Trailing P/E Ratio-3.33
Forward P/E Ratio-5.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.56 million
Price / Sales584.16
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book29.22

Profitability

EPS (Most Recent Fiscal Year)($4.48)
Net Income$-238,170,000.00
Net MarginsN/A
Return on Equity-733.88%
Return on Assets-127.21%

Miscellaneous

Employees122
Outstanding Shares61,160,000
Market Cap$929.68

The Truth About Cryptocurrencies

Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.04. View Coherus Biosciences' Earnings History.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Coherus Biosciences.

What price target have analysts set for CHRS?

5 analysts have issued 12 month price objectives for Coherus Biosciences' stock. Their predictions range from $17.00 to $45.00. On average, they expect Coherus Biosciences' stock price to reach $26.80 in the next year. This suggests a possible upside of 79.9% from the stock's current price. View Analyst Ratings for Coherus Biosciences.

What is the consensus analysts' recommendation for Coherus Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Coherus Biosciences stock?

Here are some recent quotes from research analysts about Coherus Biosciences stock:
  • 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (7/10/2018)
  • 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)

Who are some of Coherus Biosciences' key competitors?

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the folowing people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 63)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 52)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 56)
  • Dr. Barbara K. Finck, Chief Medical Officer (Age 71)
  • Dr. V. Bryan Lawlis Jr., Science Director & Director (Age 66)

Has Coherus Biosciences been receiving favorable news coverage?

News stories about CHRS stock have trended somewhat positive on Tuesday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Coherus Biosciences earned a daily sentiment score of 0.02 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.63 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.03%) and Hartwell J M Limited Partnership (0.02%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Barbara K Finck, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus Biosciences.

Which major investors are buying Coherus Biosciences stock?

CHRS stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Hartwell J M Limited Partnership. View Insider Buying and Selling for Coherus Biosciences.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $14.90.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $929.68 million and generates $1.56 million in revenue each year. The biotechnology company earns $-238,170,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Coherus Biosciences employs 122 workers across the globe.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.